Ozone M, Yagi T, Itoh H, Tamura Y, Inoue Y, Uchimura N, Sasaki M, Shimizu T, Terzano M G, Parrino L
Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan.
Pharmacopsychiatry. 2008 May;41(3):106-14. doi: 10.1055/s-2008-1058104.
A placebo-controlled randomized crossover study to investigate the effects of zolpidem on sleep stability in Japanese insomniac patients was performed using the cyclic alternating pattern (CAP) rate, a polysomnographic marker that reflects sleep instability.
Seventeen patients (5 M and 12 F, mean age: 40.4+/-13.6 years) who met the International Classification of Sleep Disorders (ICSD) criteria for psychophysiological insomnia were evaluated. During the first period, patients were administered the placebo on the first night, followed by either zolpidem or the placebo on the second night (treatment night). The second crossover period was conducted after a minimum 3-day observation. Improvement in the overnight CAP rate was the primary endpoint. Secondary endpoints included the CAP variables, conventional sleep variables, EEG arousals, subjective evaluation of sleep quality (measured by means of a visual analogue scale and the St. Mary's Hospital Sleep Questionnaire), and drug safety.
Zolpidem significantly decreased the overnight CAP rate values (57.6 vs. 39.0%, p=0.009) and improved "sleep depth" (p=0.044) and "sleep quality" (p=0.023) subjective questionnaire scores. Zolpidem also significantly improved VAS (p=0.036). The amount of time spent in sleep stages 3+4 was significantly increased by zolpidem without affecting the amounts of stage 2 and rapid eye movement (REM) sleep. Significant negative correlations were found when the sleep quality score was matched to the CAP rate (p=0.022). No serious adverse events occurred during the study.
In Japanese patients with psychophysiological insomnia, zolpidem increased sleep stability by significantly improving the overnight CAP rate. Zolpidem also improved sleep depth and sleep quality, both subjectively and objectively.
采用反映睡眠不稳定性的多导睡眠图指标——周期性交替模式(CAP)率,进行一项安慰剂对照的随机交叉研究,以调查唑吡坦对日本失眠患者睡眠稳定性的影响。
对17名符合国际睡眠障碍分类(ICSD)中精神生理性失眠标准的患者(5名男性和12名女性,平均年龄:40.4±13.6岁)进行评估。在第一阶段,患者在第一晚服用安慰剂,第二晚(治疗夜)服用唑吡坦或安慰剂。在至少3天的观察期后进行第二个交叉阶段。夜间CAP率的改善是主要终点。次要终点包括CAP变量、传统睡眠变量、脑电图觉醒、睡眠质量的主观评估(通过视觉模拟量表和圣玛丽医院睡眠问卷测量)以及药物安全性。
唑吡坦显著降低了夜间CAP率值(57.6%对39.0%,p = 0.009),并改善了“睡眠深度”(p = 0.044)和“睡眠质量”(p = 0.023)主观问卷得分。唑吡坦还显著改善了视觉模拟量表评分(p = 0.036)。唑吡坦显著增加了3+4期睡眠的时长,而不影响2期睡眠和快速眼动(REM)睡眠的时长。当睡眠质量评分与CAP率匹配时,发现显著的负相关(p = 0.022)。研究期间未发生严重不良事件。
在日本精神生理性失眠患者中,唑吡坦通过显著提高夜间CAP率增加了睡眠稳定性。唑吡坦在主观和客观上均改善了睡眠深度和睡眠质量。